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viruses. The abundant secretion of
type I interferon might activate NOX2
or other components of the nicotin-
amide adenine dinucleotide phos-
phate (NADPH)-oxidase system,which
produces reactive oxygen intermedi-
ates (ROIs). ROIs reduce endosomal
pH, which in turn prevents complete
degradation of the antigen and thereby
enhances antigen crosspresentation
(Savina et al., 2006). Although human
pDCs do not express mannose re-
ceptor, a C type lectin that favors
crosspresentation by enabling antigen
uptake into specialized endosomes
(Burgdorf et al., 2007), they might em-
ploy other mechanisms of receptor-
mediated endocytosis to crosspresent
antigens. This phenomenon could also
explain the discrepancy between the
crosspresentation of HIV peptide-lipo-
peptide conjugates and HIV-infected
apoptotic cells observed in the present
study, and the lack of crosspresenta-
tion of tumor antigens or tumor anti-
gens delivered as immune complexes
(Figure 1). It is likely that, depending
on the receptor selectively engaged,
the antigen reaches different compart-
ments and undergoes complete deg-
radation and exclusive loading onto
MHC class II or partial degradation
and further processing into the cytosol
for loading intoMHCclass I molecules.
Accordingly, myeloid DCs are more
efficient at crosspresenting HIV-gag
protein when it is targeted to human-
DEC205 receptor than when it is tar-
geted to a closely related receptor
like DC-SIGN (Bozzacco et al., 2007).
Hoeffel et al. have returned pDCs to
the center stage of antigen presenta-
tion. Clearly, it is essential to determine
whether crosspresentation by human
pDCs is a common event, especially
during HIV infection, and whether such
presentation leads to T cell stimulation
or T cell anergy in vivo. Because HIV
does not productively infect pDCs, but
activates them through TLR7, cross-
presentation by pDCs might be a very
effective way to elicit anti-HIV T cell
responses.
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The balance between kinases and phosphatases is crucial for regulating lymphocyte signaling. In
this issue, McNeill et al. (2007) show that the transmembrane phosphatase CD45 has a role as
both positive and negative regulator of T cell signaling.The presence of CD45 molecules on
hematopoietic cells has long been an
enigma: Why so much, why so big,
why so variable, why can we not find
a ligand? One of the most abundant
molecules on the lymphocyte surface,
CD45 was identified a number of years
ago as a transmembrane phosphatase
(Hermiston et al., 2003). The large ex-
tracellular domain of CD45 is notable
for its highly glycosylated and sialy-lated state, which varies depending
on the inclusion or exclusion of alter-
natively spliced exons 4, 5, and 6.
The resulting isoforms are specific
not only to hematopoietic cell type,
but also to the stage of differentiation
and activation of the cell. Not surpris-
ingly, therefore, it was suggested that
these alternative isoforms might inter-
act with unique ligands; however, con-
vincing identification of ligands spe-Immunity 27, Scific for any of the isoforms has so far
defied a seemingly endless supply of
research dollars and several lifespans
of graduate students.
The major intracellular targets of
CD45 phosphatase activity are the
Src-family kinases (SFK), which in T
cells are predominantly the family
members p56Lck (Lck) and p59Fyn
(Fyn). Lck, in particular, is a primary
initiator of signal transduction uponeptember 2007 ª2007 Elsevier Inc. 421
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PreviewsFigure 1. Regulation of Lck Activity by the Opposing Actions of Kinases and
Phosphases
The regulatory Tyr (Y505) of Lck is phosphorylated by the kinase Csk, which maintains Lck in an
inactive conformation. The dephosphorylation of Y505 by CD45 in resting T cells sustains a pool
of basally active Lck. Upon T cell stimulation, this pool of Lck auto- or transphosphorylates the
Tyr residue in the kinase domain (Y394), which in turn enhances Lck kinase activity. CD45 can
also dephosphorylate Y394, returning Lck to the basally active state.T cell receptor engagement, and the
absence of Lck leads to a severe block
in T cell differentiation and profound
impairment of activation in mature
T cells (Zamoyska et al., 2003). Con-
versely, the overexpression of Lck or
mutations that disregulate Lck func-
tion can result in uncontrolled cellular
activation and leukemogenesis. SFK
activity is regulated, in large part, by
the phosphorylation status of two key
tyrosine (Tyr) residues, one in the
kinase domain and one at the C termi-
nus. Phosphorylation of the kinase
domain Tyr (residue 394 in Lck)
enhances kinase activity, whereas
phosphorylation of the C-terminal Tyr
(residue 505 in Lck) has an inhibitory
effect (Palacios and Weiss, 2004).
CD45 was shown to dephosphorylate
the inhibitory Tyr of Lck, and CD45-
deficient mice have highly phosphory-
lated Lck Tyr-505 in the thymus and
a block in differentiation. The expres-
sion of an Lck transgene containing
Phe rather than Tyr at residue 505
overcame the CD45-deficient differ-
entiation block, confirming that Lck
Tyr-505 is a physiologically relevant
target of CD45 activity in vivo and
that dephosphorylation of this residue
by CD45 is required to enable Lck
activity [(Hermiston et al., 2003) and
references therein] (Figure 1). In addi-
tion, it has been shown that CD45
can dephosphorylate Tyr-394 in the
active site of Lck, suggesting that
CD45 might also play a role in down-422 Immunity 27, September 2007 ª2007regulating the activity of Lck (Ashwell
and D’Oro, 1999).
This dual activity of CD45, both en-
abling and downregulating Lck activ-
ity, is elegantly demonstrated in vivo
in the paper by McNeill et al. in this
issue of Immunity (McNeill et al.,
2007), with some interesting conse-
quences for thymocyte differentiation
and peripheral T cell activation. The
authors expressed transgenes encod-
ing CD45RO isoforms (normally ex-
pressed by double positive [DP] thy-
mocytes and activated T cells), which
had either wild-type or disabled phos-
phatase activity, in mice lacking en-
dogenousCD45. The expression of the
transgenes to varying amounts pro-
vided a titration of CD45 phosphatase
activity that correlated directly with
cell surface expression and ranged
from approximately 1% to 60% of
wild-type values. Curiously, lower
phosphatase activity than that ob-
tained from normal CD45 expression
was found to enhance differentiation
of mature thymocytes, with maximal
CD4SP and CD8SP differentiation
occurring with constructs expressed
at about 30% of wild-type amounts.
Remarkably, as little as 3% of normal
CD45 activity was sufficient to over-
come the differentiation block of the
CD45-deficient background and re-
store single positive (SP) differentiation
to approximately wild-type amounts.
It had been noted before that mice
heterozygous for CD45 (expressingElsevier Inc.50% of wild-type amounts) show en-
hanced positive selection of T cell re-
ceptor (TCR) transgenic cells (Wallace
et al., 1997). One explanation pro-
posed for this observation was that re-
ducing CD45 expression might benefit
selection by reducing steric hindrance.
CD45 has high amounts of glycosyla-
tion and sialylation and, therefore,
could contribute considerable nega-
tive charge to the thymocyte surface
which might potentially inhibit interac-
tion between the TCR and selecting li-
gands. McNeill et al. indicate that this
explanation is unlikely because the
expression of a kinase inactive CD45
transgene at similar amounts neither
restored nor worsened positive selec-
tion beyond that seen in the CD45-
deficient mice, indicating that the ex-
ternal domain alone contributes little
to CD45 function in the thymus. In con-
trast, a second explanation, that CD45
can act both positively and negatively
to regulate signaling, was supported
by their observations that the amounts
of Lck phospho-pTyr-505 as well as
Lck phospho-Tyr-394 were altered by
changing the expression of CD45.
The authors showed there were com-
parable increases in the amounts of
phosphorylation of both these resi-
dues at intermediate CD45 expres-
sion, suggesting that the negative in-
fluence of increased pTyr-505 might
be counterbalanced by an enhanced
positive contribution from the phos-
phorylation of pTyr-394. At very low
CD45 expression, the phosphorylation
of pTyr-505 became disproportionally
higher than the phosphorylation of
pTyr-394, resulting in decreased Lck
activity. A consequence of intermedi-
ate CD45 expression was that an in-
creased percentage of DP thymocytes
had detectable phospho-Erk and
phospho-PKB upon stimulation with
anti-CD3, indicating they were more
sensitive to TCR engagement and
therefore more likely to undergo posi-
tive selection. Similar increases in sen-
sitivity to TCR stimulation were found
in peripheral T cells, which also dis-
played enhanced Erk phosphorylation
and proliferation, from the mice ex-
pressing intermediate amounts of
CD45. An interesting aside is that the
efficiency of CD4SP cell differentiation
did not mirror exactly the efficiency of
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requiring higher amounts of CD45
(and, by inference, reduced Lck activ-
ity) to see equivalent enhancement of
selection. These results concur with
published data that showed higher
Lck activity favoredCD4 differentiation
over CD8 differentiation [(Zamoyska
et al., 2003) and references therein].
These data indicate that in T cells,
sensitivity to stimulation exhibits a
Gaussian distribution with respect to
CD45 phosphatase activity, with peak
responsiveness set just below normal
CD45 expression. Why then is the ex-
pression of CD45 so high? It has
been suggested that CD45 activity is
regulated by dimerization because
the crystal structure of the mem-
brane-proximal regions of a related
phosphatase, RPTPa, have been
shown to form a dimer in which the
catalytic sites of one molecule are oc-
cluded by binding a structural wedge
contributed by the second partner.
Similar residues are conserved in
CD45, and the artificial dimerization
of CD45 was shown to reduce its ac-
tivity. Moreover, a knockin mouse in
which a key residue required for
dimerization was mutated developed
a lymphoproliferative syndrome and
autoimmune nephritis, indicating that
dimerization is important for the nor-
mal control of peripheral T cell activa-
tion (Majeti et al., 2000). McNeill et al.
argue that the dimerization model is
unlikely to account for the decreased
phosphatase activity they observe
with increasing expression of CD45,
above 40% of that expressed by wild-
type cells, for two reasons. First, whentheymeasured phosphatase activity of
isolated cell membranes, they found a
linear increase in activity correspond-
ing to CD45 expression, whereas the
dimerizationmodel predicts that phos-
phatase activity should plateau at a
certain point, beyond which dimeriza-
tion and inhibition of CD45 activity
would bemore likely to occur. Second,
the inhibition ofCD45activity bydimer-
ization at high concentrations should
increase T cell signaling rather than
decrease signaling, as was observed.
Where does this leave us in terms
of the outstanding questions about
CD45? With respect to CD45’s abun-
dance, the data from McNeill et al.
supports the suggestion that CD45
behaves as a rheostat, regulating the
threshold of activation in T cells. How-
ever, many issues still remain. These
transgenic mice expressed the small-
est CD45RO isoforms; would a similar
titration of responsiveness be ob-
served if the larger isoforms were ex-
pressed? Although studies of trans-
genic mice expressing other single
isoforms at high amount showed only
minor differences between them (Ko-
zieradzki et al., 1997; Ogilvy et al.,
2003), perhaps this kind of titration of
expression is required to reveal unique
functions. Furthermore, the analysis of
whether the variable amounts of CD45
influence the distribution of molecules
in the immunological synapse could
provide clues as to howCD45 interacts
with its target proteins. Finally, what
about other hematopoeitic lineages?
The knockin mutation influencing
dimerization was found to cause B
cell hyperresponsiveness (HermistonImmunity 27,et al., 2005); how does the titration of
CD45 influence B cell development
and responses? Perhaps for these
cells aswell, lessCD45 ismore in terms
of maximizing responsiveness; how-
ever, more CD45 might be optimal for
setting the physiological threshold of
activation and maintaining tolerance.
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